Literature DB >> 21509263

Rapid iron loading in heart and liver in a patient with transfusion dependent thalassaemia after brief poor compliance with iron chelation therapy.

Shahina Daar1, Saeed Ahmed, Vasili Berdoukas.   

Abstract

Iron loading in patients with transfusion dependent thalassaemia is considered to occur primarily in the liver and, once the liver becomes saturated, other organs begin loading. We report here a splenectomised male patient who was treated for hepatitis C virus infection. Prior to starting antiviral therapy, his serum ferritin was maintained below 500 ng/ml with deferiprone monotherapy; cardiac T2* by magnetic resonance imaging was 48.8ms and hepatic T2* was 19.5ms. After twelve months of antiviral treatment during which time he was very poorly compliant with his deferoxamine chelation therapy, his ferritin had risen to 3820 ng/ml and cardiac and hepatic T2* findings were 12.7 ms and 14.5 ms respectively, indicating increased iron loading in both organs, but particularly in the heart. Fifteen months after recommencing combination chelation, his ferritin was 95 ng/ml and cardiac and hepatic T2* were 27.5 and 28.4ms respectively, indicating complete clearance of iron load in both organs. This case demonstrates that iron overload can develop rapidly and in some cases there is relatively rapid iron loading in the heart as compared to the liver.

Entities:  

Keywords:  Case report; Chelation therapy; Deferiprone; Deferoxamine; Iron overload; Magnetic resonance imaging; Oman; Thalassaemia Major

Year:  2010        PMID: 21509263      PMCID: PMC3074730     

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  9 in total

1.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.

Authors:  L J Anderson; S Holden; B Davis; E Prescott; C C Charrier; N H Bunce; D N Firmin; B Wonke; J Porter; J M Walker; D J Pennell
Journal:  Eur Heart J       Date:  2001-12       Impact factor: 29.983

2.  Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.

Authors:  M A Tanner; R Galanello; C Dessi; M A Westwood; G C Smith; S V Nair; L J Anderson; J M Walker; D J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2006       Impact factor: 5.364

3.  Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia.

Authors:  Athanassios Aessopos; Christina Fragodimitri; Fotios Karabatsos; Antonia Hatziliami; Jacqueline Yousef; Anastasios Giakoumis; Aikaterini Dokou; Efstathios D Gotsis; Vasilis Berdoukas; Markissia Karagiorga
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

4.  T2* cardiovascular magnetic resonance in the management of thalassemia patients in Oman.

Authors:  Shahina Daar; Anil V Pathare; Rajeev Jain; Shoaib Al Zadjali; Dudley J Pennell
Journal:  Haematologica       Date:  2008-11-10       Impact factor: 9.941

5.  Combined therapy with deferiprone and desferrioxamine.

Authors:  B Wonke; C Wright; A V Hoffbrand
Journal:  Br J Haematol       Date:  1998-11       Impact factor: 6.998

6.  Longitudinal analysis of heart and liver iron in thalassemia major.

Authors:  Leila J Noetzli; Susan M Carson; Anne S Nord; Thomas D Coates; John C Wood
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

7.  Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.

Authors:  Kallistheni Farmaki; Ioanna Tzoumari; Christina Pappa; Giorgos Chouliaras; Vasilios Berdoukas
Journal:  Br J Haematol       Date:  2009-11-12       Impact factor: 6.998

8.  Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.

Authors:  P Kirk; M Roughton; J B Porter; J M Walker; M A Tanner; J Patel; D Wu; J Taylor; M A Westwood; L J Anderson; D J Pennell
Journal:  Circulation       Date:  2009-10-02       Impact factor: 29.690

9.  Rapid iron loading in a pregnant woman with transfusion-dependent thalassemia after brief cessation of iron chelation therapy.

Authors:  Kallistheni Farmaki; Efstathios Gotsis; Ioanna Tzoumari; Vasilios Berdoukas
Journal:  Eur J Haematol       Date:  2008-05-06       Impact factor: 2.997

  9 in total
  1 in total

1.  Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine.

Authors:  Robert W Grady; Renzo Galanello; Rachel E Randolph; Dorothy A Kleinert; Carlo Dessi; Patricia J Giardina
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.